穴位注射华蟾素治疗活动性肝炎肝硬化的临床研究

Therapeutic Effect of Intra-acupoint Injection of cinobufacin on Active Cirrhosis.

目的探讨华蟾素(C inobufac in)穴位注射治疗活动性肝炎肝硬化的临床效果。方法活动性肝炎肝硬化90例,随机分为治疗组45例。对照组45例,两组均给予综合基础治疗。治疗组45例加用抗病毒药物华蟾素5 m l足三里穴位注射,每日1次,坚持3个月一疗程。结果疗程结束后,治疗组的肝功能观察指标[总胆红素(TB IL)、谷丙转氨酶(ALT)、血清白蛋白(ALB)、凝血时间(PT)]均较治疗前有明显改善(P均<0.001)。对照组的肝功能观察指标中仅TB ILI有明显改善(P<0.001),两组比较,肝功能四项观察指标均有明显差异。治疗组的血常观指标中,仅白细胞(WBC)明显升高,与治疗前有明显改善(P<0.001)。对照组血常观四项指标无改善。治疗组乙肝e抗原(HBeAg)、乙肝病毒-DNA(HBV-DNA)阴转率分别为30.3%、32.8%,对照组HBeAg、HBV-DNA阴转率分别为6.7%、14.3%,P均<0.05。结论华蟾素注射液穴位注射治疗活动性肝炎肝硬化通过抑制乙肝病毒复制、保护肝细胞等作用,明显控制肝炎肝硬化的炎症活动,安全无不良反应。

Objective To investigate the clinical effect of intra - acupoint injection of cinobufacin on chronic hepatitis B related active cirrhosis. Methods Ninety patients with cirrhosis were randomly assigned to receive cinobufacin 5ml intra - acupoint injection once daily for three months（45 patients） in addition to regular comprehensive therapy or regular comprehensive therapy alone （45 patients）. Results As compared with baseline values, at the end of treatment liver function （TBILI, ALT, ALB, PT, all P 〈 0. 001 ） improved significantly in treatment group patients, while only TBILI improved significantly in control group（ P 〈0. 001 ） In addition, the improvements in BILI, ALT, ALB, PT were significantly greater in treatment group patients than those in control group. White blood cell count significantly increased in treatment group, but not in control group. The negative conversion rates of serum HBeAg and HBV -DNA in the treatment group （30.3% and 32.8%, respectively） were significantly higher than those in control greup（6.7% and 14.3%, respectively,all P 〈0.05）. Conclusion Intra - acupoint injection of cinobufacin can inhibit viral replication, protect liver cells and control inflammation, It is safe and effective without significant side effect.